Dublin, Dec. 07, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/763qfd/nitric_oxide) has announced the addition of Jain PharmaBiotech's new report "Nitric Oxide - Therapeutics, Markets and Companies" to their offering.
This report Analyses the latest concepts of nitric oxide (NO) and the role it plays in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric oxide-based drugs are described as well as the companies involved in developing them.
Various pharmacological approaches are described along with their therapeutic relevance. Various approaches are compared using SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis. NO-based therapies are compared with conventional approaches and opportunities for combination with modern biotechnology approaches are described.
Share of drugs where NO is involved in the mechanism of action is analyzed in the worldwide pharmaceutical market for 2014 and is projected to 2019 and 2024 as new drugs with NO-based mechanisms are introduced into the market. Various strategies for developing such drugs are discussed.
Several companies have a product or products involving NO and free radicals. The report includes profiles of 34 companies involved in this area of which 8 have a significant interest in NO-based therapeutics. Other players are pharmaceutical and biotechnology companies as well as suppliers of products for NO research. Unfulfilled needs in the development of NO-based therapeutics are identified. Important 15 collaborations in this area are tabulated.
There are numerous publications relevant to NO. Selected 500 references are included in the bibliography. The text is supplemented with 25 tables and 26 figures.It is concluded that the future prospects for NO-based therapies are bright and fit in with biotechnology-based approaches to modern drug discovery and development. It is anticipated that some of these products will help in meeting the unfulfilled needs in human therapeutics.
Key Topics Covered:
Executive Summary
1. Introduction
2. Nitric Oxide Pathways
3. Role of NO in Physiology
4. Role of NO in Diseases
5. Pharmacology of Nitric Oxide
6. Therapeutic Applications
7. Evaluation of NO-Based Drugs
8. Markets for NO-based Therapies
9. Companies
10. References
For more information visit http://www.researchandmarkets.com/research/763qfd/nitric_oxide
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices


Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 



